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In recent years, lifestyle-related diseases and metabolic syndrome have been increasing due to changes in 
people's lifestyles [1]. They include obesity, diabetes, hypertension and dyslipidemia, and a particularly 
important point would be the prevention of arteriosclerosis [2]. Especially, elevated values of low-density 
lipoprotein cholesterol (LDL-C) and glycosylated hemoglobin (HbA1c) have been known to become risk 
factors for atherosclerotic cardiovascular disease (ASCVD) [3]. Consequently, control of cholesterol profile 
has become essential for coronary heart disease.  
 
From personal life point of view, the regular healthy lifestyle would be basically necessary for managing 
lipids problems [4,5]. Even if a person has some genetic increased risk for cholesterol, one can reduce the 
risk level by half degree associated with continuing adequate lifestyle [6]. For obtaining healthy lipid 
profile, maintaining optimal levels of body weight, blood glucose and physical activity would be beneficial 
as well as reducing of intake of refined carbohydrates and simple sugars [7,8]. After these recommended 
healthy strategies were tried, pharmacotherapy would be considered.  
 
Historically speaking, it was the Framingham Heart Study that has identified cholesterol as one of the risk 
factors for coronary heart disease [9]. After that, there have been lots of papers and randomized clinical 
trials (RCTs), in which elevated LDL-C would be a major factor to ASCVD [10]. Consequently, beneficial 
managements for lipid profile have included the predominant target of apolipoprotein B, LDL-C, 
non-HDL-C and triglyceride (TG) [11].  
 
Recently, there were some guidelines for clinical management for lipids. The American College of 
Cardiology–American Heart Association (ACC–AHA) published the guideline in 2018 [8]. Successively in 
the next year, it presented the guidelines for primary prevention of cardiovascular disease. Both have 
shown the recommendations for evaluation of risk factors and adequate management of lipid profile [5]. 
By utilizing these guidelines, physicians can give preferable management of lipid profile for clinical 
prevention of ASCVD.  
 
From these situations mentioned above, this article introduces some hints and tips that will help 
clinicians in their daily medical practice. It cannot cover everything, but most common five suggestions 
are described. 
  
Firstly, LDL-C is recommended to be reduced. The direct relationship has been reported between LDL-C 
value and the risk of atherosclerotic cardiovascular disease [12]. Then, there has been the 
recommendation that can simply describe “lower is better”. As to the value of LDL-C, each 39 mg/dL 
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decrease would reduce cardiovascular events by 22% and overall mortality by 10% [13]. Furthermore, 
not only the conventional upper limit of LDL but also the reduction percentage has been described in 
recent guidelines [13]. It has been meaningful for the present of a linear correlation between LDL-C and 
cardiovascular risk.  
 
From data of 29069 patients with statin therapy, LDL-C showed 39% of reduction without a significant 
change in lipoprotein(a) [14]. As a result, elevated baseline and on-statin lipoprotein(a) have showed the 
presence of approximately linear relation with cardiovascular disease risk. Furthermore, the magnitude of 
event reduction has reported to be proportional to the reduced degree of LDL-C [12,15]. Consequently, 
both of the degree of absolute risk and reduced ratio of LDL-C achieved have been important.  
 
Secondly, physician will talk with the patient about the risk factors and show the risk for the next 10 years 
[13,16]. When boundary value is found, coronary artery calcium (CAC) score could be also performed and 
calculated. Risk factors for ASCVD include the following: high blood pressure, diabetes, smoking, 
pre-eclampsia, early menopause, rheumatic disease, HIV infection, family history of young coronary artery 
disease, South Asian ancestry, chronic kidney disease (CKD), elevated triglyceride, ankle-brachial index 
(ABI) <0.9, high sensitivity C-reactive protein (CRP) > 2mg/L, high lipoprotein (a) and high apolipoprotein 
B .  
 
Calculating the risk of ASCVD (ACC / AHA, next 10 years) requires age, gender, race, T-cho, HDL-C, SBP, 
DBP, hypertension treatment, history of diabetes and smoking. The possible estimated age ranges 40-75 
years old. Value of LDL-C must be maintained during 70-190 mg / dL [13,16].  
 
Thirdly, there are strong recommendations for diabetes and previous cardiovascular disease [13]. The 
guideline recommends statin therapy for patients 40-75 years with LDL-C more than 69 mg/dL who have 
diabetes or a 10-years risk of ASCVD equal to or greater than 7.5% [13].  Similarly, additional 
considerations should be made for younger or older adults. Medical staff calculates patient’s 10-year risk 
of ASCVD, and then risk assessment can be individualized by considering any risk-enhancing factors [13]. 
The patient’s CAC score would be measured, if the situation is possible. 
 
Fourthly, key points from the 2018 ACC-AHA guidelines were described in scheme for everyone to 
understand easily and well [13]. It includes a) promote a healthy lifestyle, b) share decision making with 
the patient, c) determine candidates for pharmacotherapy, d) adopt a personalized approach and e) 
monitor responses to treatment and lifestyle.  
 
There are several important managements in the part c) as follows: i) reduce LDL-C level by >= 50% with 
high-intensity statin for clinical ASCVD, ii) prescribe high-intensity statin (up to highest tolerated dose) 
and consider addition of nonstatin if needed for severely elevated LDL-C, iii) prescribe moderate-intensity 
statin and consider reducing LDL-C by >= 50% in diabetic patients at high risk, iv)  reduce LDL-C by >= 
30% for 10-yr risk of ASCVD >= 7.5% (or >= 50% if 10-yr risk >= 20%) [13].  
 
Finally, a science advisory from the AHA has published the latest comments [17]. Among them, there are 
several key points about the relationship between dietary cholesterol and cardiovascular risk: a) previous 
guideline has eliminated specific dietary cholesterol target recommendation, then its role for CVD has 
been evaluated, b) a variety of meat contribute 42% of the total cholesterol intake, eggs 25%, and other 
food groups about a third, c) observational studies with 250,000 subjects from 1980-2012 have not 
shown the association between dietary cholesterol and CVD risk, and similarly egg intake is not associated 
with CVD risk, d) most observational studies of cholesterol intake on CVD risk are limited in value, and 
randomized controlled diet interventions showed a dose-response relationship, where every 100 mg/day 
increase in dietary cholesterol predicted an LDL-C increase of 1.90-4.58 mg/dl depending on the model, e) 
heart-healthy dietary patterns (Mediterranean-style and DASH-style diets) have a relatively high ratio of 
PUFA to saturated fatty acid and are low in cholesterol with typical menus. They are characterized by 
fruits, vegetables, whole grains, low-fat or fat-free dairy products, lean protein sources, nuts, seeds, and 
vegetable oils [17].  
 
In summary, this article described current topics concerning the medical issues between cholesterol and 
ASCVD in the light of standard guideline. Furthermore, some related matters such as heart-healthy dietary 
patterns were also introduced. Author expects this report would become some reference in actual clinical 
practice.  
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